A novel treatment strategy for pancreatic cancer based on gene profiles

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Pancreatic cancer has one of the highest rates of mortality among malignancies and the development of promising future therapies is strongly required. Recently, the utility of gene aberrations as biomarkers for determining therapeutic strategies has been demonstrated in several types of cancer. The detection of druggable mutations that aid in the selection of effective molecular targeting drugs is feasible in clinical settings for certain cancers. On the other hand, personalized therapy for pancreatic cancer guided by genomic biomarkers has not yet been realized and suitable molecular targets for the disease have been unclear until now. KRAS, CDKN2A, TP53, and SMAD4 have been recognized as major driver genes in pancreatic carcino-genesis. However, it is considered difficult to develop treatment strategies to target genetic aberrations of these four genes. In recent years, genome sequencing has progressively revealed the molecular biological characteristics of pancreatic cancer, including the discovery of novel potential therapeutic targets and low-frequency druggable genetic aberrations. Gene profile-based novel treatment strategies and subsequent attempts to realize precision medicine for pancreatic cancer are steadily ongoing in an effort to achieve improved treatment outcomes.

Original languageEnglish
Pages (from-to)1326-1331
Number of pages6
JournalJapanese Journal of Cancer and Chemotherapy
Volume43
Issue number11
Publication statusPublished - 2016 Nov 1
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Genes
Therapeutics
Biomarkers
Neoplasms
Precision Medicine
Drug Delivery Systems
Genome
Mutation
Mortality

Keywords

  • Clinical sequencing
  • Genomic biomarker
  • Precision medicine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A novel treatment strategy for pancreatic cancer based on gene profiles. / Hayashi, Hideyuki; Nishihara, Hiroshi.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 43, No. 11, 01.11.2016, p. 1326-1331.

Research output: Contribution to journalArticle

@article{75d18be0d3d346768f25a81ba31234a7,
title = "A novel treatment strategy for pancreatic cancer based on gene profiles",
abstract = "Pancreatic cancer has one of the highest rates of mortality among malignancies and the development of promising future therapies is strongly required. Recently, the utility of gene aberrations as biomarkers for determining therapeutic strategies has been demonstrated in several types of cancer. The detection of druggable mutations that aid in the selection of effective molecular targeting drugs is feasible in clinical settings for certain cancers. On the other hand, personalized therapy for pancreatic cancer guided by genomic biomarkers has not yet been realized and suitable molecular targets for the disease have been unclear until now. KRAS, CDKN2A, TP53, and SMAD4 have been recognized as major driver genes in pancreatic carcino-genesis. However, it is considered difficult to develop treatment strategies to target genetic aberrations of these four genes. In recent years, genome sequencing has progressively revealed the molecular biological characteristics of pancreatic cancer, including the discovery of novel potential therapeutic targets and low-frequency druggable genetic aberrations. Gene profile-based novel treatment strategies and subsequent attempts to realize precision medicine for pancreatic cancer are steadily ongoing in an effort to achieve improved treatment outcomes.",
keywords = "Clinical sequencing, Genomic biomarker, Precision medicine",
author = "Hideyuki Hayashi and Hiroshi Nishihara",
year = "2016",
month = "11",
day = "1",
language = "English",
volume = "43",
pages = "1326--1331",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "11",

}

TY - JOUR

T1 - A novel treatment strategy for pancreatic cancer based on gene profiles

AU - Hayashi, Hideyuki

AU - Nishihara, Hiroshi

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Pancreatic cancer has one of the highest rates of mortality among malignancies and the development of promising future therapies is strongly required. Recently, the utility of gene aberrations as biomarkers for determining therapeutic strategies has been demonstrated in several types of cancer. The detection of druggable mutations that aid in the selection of effective molecular targeting drugs is feasible in clinical settings for certain cancers. On the other hand, personalized therapy for pancreatic cancer guided by genomic biomarkers has not yet been realized and suitable molecular targets for the disease have been unclear until now. KRAS, CDKN2A, TP53, and SMAD4 have been recognized as major driver genes in pancreatic carcino-genesis. However, it is considered difficult to develop treatment strategies to target genetic aberrations of these four genes. In recent years, genome sequencing has progressively revealed the molecular biological characteristics of pancreatic cancer, including the discovery of novel potential therapeutic targets and low-frequency druggable genetic aberrations. Gene profile-based novel treatment strategies and subsequent attempts to realize precision medicine for pancreatic cancer are steadily ongoing in an effort to achieve improved treatment outcomes.

AB - Pancreatic cancer has one of the highest rates of mortality among malignancies and the development of promising future therapies is strongly required. Recently, the utility of gene aberrations as biomarkers for determining therapeutic strategies has been demonstrated in several types of cancer. The detection of druggable mutations that aid in the selection of effective molecular targeting drugs is feasible in clinical settings for certain cancers. On the other hand, personalized therapy for pancreatic cancer guided by genomic biomarkers has not yet been realized and suitable molecular targets for the disease have been unclear until now. KRAS, CDKN2A, TP53, and SMAD4 have been recognized as major driver genes in pancreatic carcino-genesis. However, it is considered difficult to develop treatment strategies to target genetic aberrations of these four genes. In recent years, genome sequencing has progressively revealed the molecular biological characteristics of pancreatic cancer, including the discovery of novel potential therapeutic targets and low-frequency druggable genetic aberrations. Gene profile-based novel treatment strategies and subsequent attempts to realize precision medicine for pancreatic cancer are steadily ongoing in an effort to achieve improved treatment outcomes.

KW - Clinical sequencing

KW - Genomic biomarker

KW - Precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85013809112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013809112&partnerID=8YFLogxK

M3 - Article

C2 - 27899773

AN - SCOPUS:85013809112

VL - 43

SP - 1326

EP - 1331

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 11

ER -